Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNasdaq:BDSI
Date8/2002
Raised
Post IPO Valuation

General Information

Websitebdsi.com
CategoryBioTech
Phone919-582-9050
Employees

Offices

Raleigh, USA
801 Corporate Center Drive, Suite 210
Raleigh, NC, 27607
USA

People

Chief Financial Officer
President and Chief Executive Officer
Vice President, Marketing and Corporate Development
Board of Directors
Board of Directors
Board of Directors
Lead Director
Executive Vice President of Product Development
Show All People

Funding

TOTAL $40M
POST IPO FUNDING TOTAL $40M
Post IPO Equity, 11/2012
$40M
DEBT TOTAL $20M
Debt, 7/2013
$20M

Tags

BioDelivery Sciences International

BioDelivery Sciences (“BDSI”®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA®) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

Recent Milestones

Videos

Screenshots

BioDelivery Sciences International screenshot
Above: BioDelivery Sciences International
Uploaded: 12/1/12

Stock Price

Sources

  1. BioDelivery Sciences Announces $40 Million Registered Financing (finance.yahoo.com) [edit]
  2. BDSI secures $20M loan to advance drug application (bizjournals.com) [edit]
Edit This Page
Last Edited 12/23/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy